Since the serum GM3(d18:1-16:0) and GM3(d18:1-24:1) levels were significantly higher in the patients with lymphoid neoplasms, we investigated the correlation between the serum GM3 molecular species levels and CRP, soluble interleukin-2 receptor (sIL-2R), or lactate dehydrogenase (LD), which are usually used as a biomarker for lymphoma in clinical practice. This evidence concerns the gene CRP and lymphoma.